ALIM was +63% and PSDV was +35% yesterday on news that FDA will not require a new clinical trial to satisfy the terms of the Iluvien CRL issued in October:
I haven't followed this at all, but I think you are over-stating. Perhaps FDA said "we will not RTF if you resubmit without a new study"